NEW YORK (GenomeWeb) – Becton Dickinson said today that its BD Max MDR-TB panel has received CE-IVD status and is now available in Europe.

The PCR-based panel is intended to help detect tuberculosis-causing bacteria and determine if the bacteria contains mutations associated with resistance to isoniazid and rifampicin, two important first-line TB drugs.

The assay runs on the BD Max system, a fully integrated and automated molecular diagnostics platform that can run up to 24 samples across multiple tests and provides results for most assays in less than three hours.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.

In an editorial, Nature calls for the end to the exploitation of foreign postdocs.

Bloomberg profiles IndieBio, a startup incubator for the life sciences.

In Nucleic Acids Research this week: collection of epigenome-wide association study data, updated BloodSpot database, and more.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.

Dec
03
Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the National Institutes of Health evaluated a novel in situ hybridization approach and applied it to study splice variants related to schizophrenia.

Dec
12
Sponsored by
Illumina

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.